Evaluation of the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease

Inclusion Criteria: * Patients \>= 50 years of age, to reflect the population that will be treated and to avoid younger populations who may be suffering dementia from a cause other than Alzheimer's Disease. * Patients with Global Deterioration Scale (GDS) between 3 to 5 points (inclusive). * Clinical Dementia Rating (CDR) - GS score 1-2 at screening. * Patients with permeable airways. * Patients (or caregiver, if the patient cannot) grant consent to participate in the study by signing the informed consent form. * Patient with caregiver is physically and mentally willing to collaborate with the investigation. * Mini-Mental State Examination (MMSE) score between 14 and 26 (inclusive) at screening Exclusion Criteria: * Evident mental disability or other limitation that prevents the patient or caregiver from administering the study evaluations. * Patients with neurological symptoms or signs that suggest another cause of dementia. * Skull trauma or recent intracranial surgery. * Known clotting disorders. * Use of anticoagulants, a medication to prevent harmful blood clots (warfarin, heparin or NOAC). * Patients where coexistence of another disease or condition that may lead to significant disability (cancer, septic embolism, endocarditis, myeloproliferative disease, creatinine\> 3 mg / dl (265µmol / L), hyperkalemia \> 5.0 mmol / L, chronic/severe liver or kidney or heart disorders. * Patients with a history of hypersensitivity to rhEPO. * Patients with known allergy to any ingredients of the product. * Patients who present nasal irritation (sneezing) or a runny nose before starting treatment. * Patients who present asthma attack at the beginning of the treatment. * Patients receiving treatment with AChE-I or Memantine who are not stable for 12-weeks prior to screening. * Patients receiving treatment with psychoactive that can compromise the clinical trial results or neuropsychological tests. * Patients with a history of alcoholism and/or drug dependence. * Patients with chronic rhinosinusitis. * Have a history of abnormal nasal or sinus symptoms. * Have prior skull fracture or abnormality (nasal defect, deviated septum). * Have recent nasal trauma (fracture in the last 2 months). * Have any prior sinus or nose surgery (rhinoplasty). * Have known bleeding problem (low platelets-thrombocytopenia), recurrent nose bleeds (\>3 year). * Have acute inflammation inside the nose. * Congenital cranial facial disorders.